COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec
Bolt Metals Corp. completes successful airborne MobileMT survey over Northwind property in Quebec utilizing advanced technology for identifying mineral targets. Adopts Semi-Annual Reporting to reduce financial burden. Qualified Person approves technical content -
COMMUNIQUÉ DE PRESSE
LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories
Neuland Laboratories Limited orders raw materials for Phase 1 of macromolecule-enabled transdermal delivery development with LIR Life Sciences Corp. to advance needle-free, skin-applied peptide therapies -
COMMUNIQUÉ DE PRESSE
GLG Life Tech Corporation Reports 2026 First Quarter Financial Results
GLG Life Tech Corporation announces financial results for Q1 2026 with a 26% decrease in revenues. The Company focuses on managing cash flows and improving performance amid competitive price pressure in sweetener market -
COMMUNIQUÉ DE PRESSE
Molten Metals Completes Airborne Geophysical Survey at Texas Project
Molten Metals Corp. completes MobileMT geophysical survey at Texas Project, allowing for refined drilling targets. Focus on key properties following lapsing of Gathering Lake and Triangle Lake projects. Move to semi-annual financial reporting to reduce burden -
COMMUNIQUÉ DE PRESSE
Redwood AI Announces Collaboration with Resilience Biosciences Inc. to Advance AI-Assisted Small-Molecule Drug Development
Redwood AI Corp. collaborates with Resilience Biosciences Inc. for AI-assisted computational chemistry workflows to enhance small-molecule drug development. The partnership aims to streamline early discovery work in the life sciences sector -
-
-
COMMUNIQUÉ DE PRESSE
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
Nanobiotix fully exercises underwriters' over-allotment option, raising gross proceeds of approximately $100 million from global offering. Proceeds allocated for development and general corporate purposes -
COMMUNIQUÉ DE PRESSE
Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Abivax présente ses résultats financiers du T1 2026 et les données de l'étude 108 sur l'obéfazimod dans la RCH. Analyse intermédiaire confirme une rémission clinique durable chez les patients
